204 related articles for article (PubMed ID: 37854597)
1. Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults.
Dos Santos RS; Guzman-Llorens D; Perez-Serna AA; Nadal A; Marroqui L
Front Immunol; 2023; 14():1263926. PubMed ID: 37854597
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.
Coomans de Brachène A; Castela A; Op de Beeck A; Mirmira RG; Marselli L; Marchetti P; Masse C; Miao W; Leit S; Evans-Molina C; Eizirik DL
Diabetes Obes Metab; 2020 Oct; 22(10):1827-1836. PubMed ID: 32476252
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes.
Marroqui L; Dos Santos RS; Op de Beeck A; Coomans de Brachène A; Marselli L; Marchetti P; Eizirik DL
Diabetologia; 2017 Apr; 60(4):656-667. PubMed ID: 28062922
[TBL] [Abstract][Full Text] [Related]
4. Pro-inflammatory cytokines induce cell death, inflammatory responses, and endoplasmic reticulum stress in human iPSC-derived beta cells.
Demine S; Schiavo AA; Marín-Cañas S; Marchetti P; Cnop M; Eizirik DL
Stem Cell Res Ther; 2020 Jan; 11(1):7. PubMed ID: 31900242
[TBL] [Abstract][Full Text] [Related]
5. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
6. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
7. TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells.
Marroqui L; Dos Santos RS; Fløyel T; Grieco FA; Santin I; Op de Beeck A; Marselli L; Marchetti P; Pociot F; Eizirik DL
Diabetes; 2015 Nov; 64(11):3808-17. PubMed ID: 26239055
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice.
Syed F; Ballew O; Lee CC; Rana J; Krishnan P; Castela A; Weaver SA; Chalasani NS; Thomaidou SF; Demine S; Chang G; Coomans de Brachène A; Alvelos MI; Marselli L; Orr K; Felton JL; Liu J; Marchetti P; Zaldumbide A; Scheuner D; Eizirik DL; Evans-Molina C
bioRxiv; 2024 May; ():. PubMed ID: 38766166
[TBL] [Abstract][Full Text] [Related]
9. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress.
Lombardi A; Tomer Y
J Autoimmun; 2017 Jun; 80():48-55. PubMed ID: 28238527
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
[TBL] [Abstract][Full Text] [Related]
11. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
Wang J; Batista VS; Bunick CG
bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
[TBL] [Abstract][Full Text] [Related]
12. The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α.
Chandra V; Ibrahim H; Halliez C; Prasad RB; Vecchio F; Dwivedi OP; Kvist J; Balboa D; Saarimäki-Vire J; Montaser H; Barsby T; Lithovius V; Artner I; Gopalakrishnan S; Groop L; Mallone R; Eizirik DL; Otonkoski T
Nat Commun; 2022 Oct; 13(1):6363. PubMed ID: 36289205
[TBL] [Abstract][Full Text] [Related]
13. Distinct differences in the responses of the human pancreatic β-cell line EndoC-βH1 and human islets to proinflammatory cytokines.
Oleson BJ; McGraw JA; Broniowska KA; Annamalai M; Chen J; Bushkofsky JR; Davis DB; Corbett JA; Mathews CE
Am J Physiol Regul Integr Comp Physiol; 2015 Sep; 309(5):R525-34. PubMed ID: 26084699
[TBL] [Abstract][Full Text] [Related]
14. IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells.
Coomans de Brachène A; Dos Santos RS; Marroqui L; Colli ML; Marselli L; Mirmira RG; Marchetti P; Eizirik DL
Diabetologia; 2018 Mar; 61(3):636-640. PubMed ID: 29305625
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the functional and transcriptomic effects of pro-inflammatory cytokines on human EndoC-βH5 beta cells.
Frørup C; Gerwig R; Svane CAS; Mendes Lopes de Melo J; Henriksen K; Fløyel T; Pociot F; Kaur S; Størling J
Front Endocrinol (Lausanne); 2023; 14():1128523. PubMed ID: 37113489
[TBL] [Abstract][Full Text] [Related]
16. First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.
Catlett IM; Aras U; Hansen L; Liu Y; Bei D; Girgis IG; Murthy B
Clin Transl Sci; 2023 Jan; 16(1):151-164. PubMed ID: 36325947
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity profile of the human EndoC-βH1 beta cell line to proinflammatory cytokines.
Gurgul-Convey E; Mehmeti I; Plötz T; Jörns A; Lenzen S
Diabetologia; 2016 Oct; 59(10):2125-33. PubMed ID: 27460666
[TBL] [Abstract][Full Text] [Related]
18. Proinflammatory cytokines induce rapid, NO-independent apoptosis, expression of chemotactic mediators and interleukin-32 secretion in human pluripotent stem cell-derived beta cells.
Dettmer R; Niwolik I; Cirksena K; Yoshimoto T; Tang Y; Mehmeti I; Gurgul-Convey E; Naujok O
Diabetologia; 2022 May; 65(5):829-843. PubMed ID: 35122482
[TBL] [Abstract][Full Text] [Related]
19. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
20. Marburg virus evades interferon responses by a mechanism distinct from ebola virus.
Valmas C; Grosch MN; Schümann M; Olejnik J; Martinez O; Best SM; Krähling V; Basler CF; Mühlberger E
PLoS Pathog; 2010 Jan; 6(1):e1000721. PubMed ID: 20084112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
